Could Akcea Therapeutics Inc (NASDAQ:AKCA) Go Up After Its Newest Short Interest Report?

June 17, 2018 - By Adrian Mccoy

The stock of Akcea Therapeutics Inc (NASDAQ:AKCA) registered an increase of 6.52% in short interest. AKCA’s total short interest was 5.37M shares in June as published by FINRA. Its up 6.52% from 5.04 million shares, reported previously. With 201,900 shares average volume, it will take short sellers 27 days to cover their AKCA’s short positions. The short interest to Akcea Therapeutics Inc’s float is 36.21%.

The stock increased 2.42% or $0.59 during the last trading session, reaching $24.95. About 355,230 shares traded or 12.13% up from the average. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $2.14 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

More notable recent Akcea Therapeutics, Inc. (NASDAQ:AKCA) news were published by: Nasdaq.com which released: “Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS” on June 13, 2018, also Seekingalpha.com with their article: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” published on June 08, 2018, Nasdaq.com published: “Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected …” on June 12, 2018. More interesting news about Akcea Therapeutics, Inc. (NASDAQ:AKCA) were released by: Globenewswire.com and their article: “New Research Coverage Highlights Cision Ltd., FCB Financial, Akcea Therapeutics, RE/MAX, Pain Therapeutics, and …” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “8 Stocks Moving In Tuesday’s After-Hours Session” with publication date: June 12, 2018.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.